Novel Small Molecule Therapies in Rheumatoid Arthritis

Slides:



Advertisements
Similar presentations
NSAIDs 1 st line of therapy in the medical management of RA.
Advertisements

Treatment Management of Rheumatoid Arthritis. Findings and In Depth Analysis.
Phase 2 of new ARVs BMS , prodrug of BMS (attachment inhibitor) - AI Study.
ONE HEALTH DR. Theo Kanellos Director, Strategic Alliances Zoetis International Services.
JAK-STAT Signaling Pathway.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update Smolen.
N Engl J Med 2012;367: Dae youn.kim/Prof.Chang hyun Lee.
Learning Objectives Describe the relationship between the JAK-STAT signaling pathway and pathogenesis of inflammatory bowel disease. Summarize the latest.
Pearls and Practical Considerations for Biologic Agents
A NEW LOOK AT RA Interactive Hot Topics Series
Rheumatoid arthritis The Lancet
New Treatments for Rheumatoid Arthritis
Highlights From San Francisco 2015
Clinical Trials in IBD.
Psoriatic Arthritis.
Introduction/Background
Clinical Developments in Inflammatory Arthritis 2017
Introduction/Background
Introducing JAK Inhibitors in Rheumatoid Arthritis
Current and Emerging Treatments for IBD
Diagnosing Rheumatoid Arthritis Early
Nat. Rev. Rheumatol. doi: /nrrheum
Part 1: Disease Activity Measures
From Conference to Practice: Big Data in Psoriasis
Expert Insights on Psoriatic Arthritis From Washington, DC
Getting the Best out of Guidelines in the Rapidly Changing Landscape of RA Treatment.
Minding the Gap Rheumatoid Arthritis Advances From London 2016
What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data  
Clinical Updates in RA: New Developments and Insights From Washington
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Cell Communication.
Is RA Treatment Addressing the Real Needs of Patients?
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
Emerging Atopic Dermatitis Treatments:
What’s new in my specialty- Rheumatoid Arthritis
Understanding Comparative Effectiveness Data in Psoriatic Arthritis
The JAK-STAT Pathway and Graft-vs-Host Disease
Evolving Treatment Landscape for PsA
Biotherapeutics.
Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.
Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.
Advancing the Treatment of IBD With Biologics
I PRO' -.._ r.. f FOLLOW I 0.
Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.
Advances in Rheumatoid Arthritis Management
What's New in Therapeutic Options for Moderate to Severe RA?
New Classes of Therapy in Multiple Myeloma
Advancing Patient Care in RA
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Viewpoints of Practicing Rheumatologists: Case Discussions in RA
Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway
Update on the Management of Atopic Dermatitis
Updates in RA, PsA, and Biosimilars
Essential Updates for PsA: A Complex Disease to Manage
Patient disposition through 48 weeks in RA-BEYOND
Tailoring Therapy in the Newly Diagnosed Patient With CLL
Intercellular Networks Underlying Developmental Decisions
Nat. Rev. Rheumatol. doi: /nrrheum
Safety and PK of Subcutaneous GS-6207, a Novel HIV-1 Capsid Inhibitor
Rheumatoid Arthritis.
Patient disposition after 2 years of treatment.
Novel therapies for chronic myelogenous leukemia
Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.
Treatment Advances for RA
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
Meet the JAKs.
You Don't Know JAK in IBD.
Presentation transcript:

Novel Small Molecule Therapies in Rheumatoid Arthritis

Introduction

Biologic Agents in RA

Biologic Agents: MOAs

Using Biologics in RA

Intracellular Kinases

JAK Inhibitors

Emerging JAK Inhibitors

Transduction in Pairs: JAK/STAT Signaling Pathways

Baricitinib: Phase 3 Studies

Some Unanswered Questions

Tofacitinib Phase 3 Studies

Baricitinib Safety: RA-BEAM

Tofacitinib and Baricitinib Monotherapy: Similar Results

Baricitinib vs ADA: RA-BEAM

Earlier Use of JAKs/Biologics

Baricitinib Dose Step-Down

Common Safety Concerns with DMARDs

Baricitinib Safety

Herpes Zoster in RA

PROs with Baricitinib: RA-BEGIN

Filgotinib: JAK 1 Inhibitor

ACR20/50/70 Findings: 3 QD Doses

PROs: QD vs BID Filgotinib

Filgotinib Safety

Summary

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.